Later this week, the FDA plans to approve, as the first outpatient COVID drugs, therapeutics that are extremely dangerous and unproven, even as the agency goes to war against cheap, safe, and proven drugs with a track record of no serious adverse events.
Newsweek review of financial filings in Congress has found that lawmakers who are driving legislation to protect Uyghurs in China are also invested—either directly in the form of stocks, or indirectly via mutual funds—in major companies tied to the oppression in Xinjiang.